Suicidal Behavior Among Schizophrenic Patients

NCT ID: NCT07145840

Last Updated: 2025-08-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-30

Study Completion Date

2023-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aimed to; -

1. Study suicidal behavior among sample of schizophrenic patients.
2. Study relation between schizophrenic symptoms and suicidal behavior.
3. Study the relation of mood symptoms in schizophrenic patients and suicidal behavior.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Suicide is a major public health concern. According to the World Health Organization (WHO), approximately one million people die by suicide each year worldwide. This statistic means that every 40 seconds, someone dies by suicide somewhere on the globe, with many more people making non-lethal suicide attempts. It has been suggested that the number of individuals who attempt suicide without causing death is about 10-15 times the number of those who die by suicide.

Schizophrenia is a severe psychiatric disorder characterized by cognitive impairment and behavioral dysfunction. Patients with schizophrenia are at an elevated risk of self-harm, suicide, and all-cause mortality, which results in a reduction of life expectancy of up to 20 years compared with the general population.

Suicide risk in schizophrenia is notably high, and early detection depends on recognizing and evaluating clinical manifestations of depression, despair, and hopelessness, as well as the nature and severity of the psychotic experience, particularly in recently diagnosed patients with higher cognitive function and educational backgrounds.

There is a lack of studies on suicidal behaviors in schizophrenic patients in Arab countries. A study on overall suicidality in Arab countries reported a lifetime suicide attempt rate of 0.72%-6.3% and a suicide ideation rate of 2.09%-13.9%. More research is needed in this area due to the societal and economic costs of suicidal behavior in schizophrenic patients. This issue is a high priority for public health. Several trials have aimed to identify valid predictors of suicide risk. These predictors could not only help reduce the mortality associated with suicidality but also enable a more rational allocation of resources for treatment. Previous suicide attempts, depressive symptoms, hopelessness, and akathisia have been identified as reliable predictors of suicidal behavior.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Suicidal Behavior Schizophrenic Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

Patients with schizophrenia. They had a current history of suicide ideation or attempt.

Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)

Intervention Type OTHER

Psychiatric interview for diagnosis of schizophrenia by SCID 5 (American Psychiatric Association, 2015), The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) is a semi structured interview guide for making the major DSM-5 diagnoses using the chapter of schizophrenia spectrum

Group B

Patients with schizophrenia without any history of neither suicide ideation nor attempt.

Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)

Intervention Type OTHER

Psychiatric interview for diagnosis of schizophrenia by SCID 5 (American Psychiatric Association, 2015), The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) is a semi structured interview guide for making the major DSM-5 diagnoses using the chapter of schizophrenia spectrum

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)

Psychiatric interview for diagnosis of schizophrenia by SCID 5 (American Psychiatric Association, 2015), The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) is a semi structured interview guide for making the major DSM-5 diagnoses using the chapter of schizophrenia spectrum

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age between 18 and 60.
2. Both females and males will be included.
3. All patients should meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for schizophrenia.

Exclusion Criteria

1. Any neurological disorder.
2. Past history of head trauma.
3. Medical or autoimmune disorders.
4. Other psychiatric disorders e. g. bipolar disorders, post-traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD), and anxiety.
5. Pregnancy.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tanta University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

asmaa

Resident of Neuropsychiatry Department, Faculty of Medicine, Tanta University, Tanta, Egypt.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tanta University

Tanta, El-Gharbia, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

35394/4/22

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.